ARPA-H commits up to $100 million to objective measures for mental health treatment
The EVIDENT program aims to replace trial-and-error psychiatric care with quantitative data, including for neuromodulation therapies.
The US health research agency ARPA-H has launched EVIDENT, a program of up to $100 million to develop quantitative measures of mental and behavioral health. The goal is to track how individuals respond to treatment so clinicians can choose effective therapies faster. EVIDENT covers neuromodulation, neuroplastogens and digital therapeutics, and includes a shared data repository from clinical trials.
Objective biomarkers are a long-standing gap in psychiatry, and better measurement could speed adoption of brain stimulation treatments such as TMS.
Learn more: Neural data · ARPA-H